查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1494909

到 2030 年血糖监测系统市场预测：按产品类型、技术、应用、分销管道、最终用户和地区进行的全球分析

Blood Glucose Monitoring Systems Market Forecasts to 2030 - Global Analysis By Product Type, Technology, Application, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2024 年全球血糖监测系统市场规模为 180.2 亿美元，预计预测期内复合年增长率为 6.8%，到 2030 年将达到 267.4 亿美元。

血糖监测系统是一种旨在测量和监测糖尿病患者血糖值的医疗设备。这些系统通常包括血糖仪、试纸、自我检查刺采血针以及提供即时血糖读数的连续血糖监测系统。准确的监测可以帮助糖尿病患者及时调整药物、饮食和生活方式，进而控制疾病。

根据国际糖尿病联盟（IDF）估计，2021年约有5.37亿成年人将患有糖尿病，预计到2045年这一数字将达到约7.83亿。

糖尿病盛行率上升

全球糖尿病盛行率的增加是血糖监测系统市场的主要驱动因素。随着被诊断为糖尿病的人数持续增加，对有效血糖监测解决方案的需求不断增加。定期血糖监测对于糖尿病管理至关重要，可以让患者追踪血糖浓度，就饮食、运动和药物做出明智的决定，并预防併发症。糖尿病负担的增加和人们对血糖控制重要性的认识不断提高，促使人们采用先进的血糖监测系统。

昂贵的设备

这些先进设备通常价格昂贵，这可能会限制其可及性和采用率，特别是在价格敏感的市场和无力负担费用的患者中。与试纸和感测器等消耗品相关的持续费用进一步增加了成本负担。高昂的初始成本和经常性费用可能会阻止一些患者和医疗保健提供者采用先进的血糖监测技术，从而阻碍市场扩张。

扩大家庭医疗保健

随着人们对糖尿病等慢性疾病的远端监测和自我管理的偏好，对使用者友好且高度连接、可在家中轻鬆使用的血糖监测设备的需求不断增长。透过将血糖监测系统与远端医疗平台和行动医疗应用程式集成，患者可以与医疗保健提供者即时共用血糖值资料，从而促进远距会诊和个人化治疗调整。家庭医疗保健服务的扩展和数位健康技术的采用预计将推动先进血糖监测系统的普及。

仿冒品

假冒设备、试纸和感测器可能会危及患者安全并导致血糖读数不准确，从而导致糟糕的治疗决策和负面的健康结果。仿冒品可能没有必要的品管和监管核准，其使用可能会削弱患者对合法血糖监测系统的信心。面对假冒产品的威胁，製造商面临保护智慧财产权和确保产品正品的挑战。

COVID-19 的影响：

COVID-19 大流行凸显了糖尿病远端监测和自我管理的重要性。由于医疗机构关闭和使用机会减少，许多患者依靠家庭血糖监测来管理自己的病情。这场大流行加速了远端医疗和远端监测解决方案的采用，包括连网血糖监测系统。然而，疫情扰乱了供应链，导致产品上市和监管核准延迟，暂时影响了市场成长。

预计自我血糖监测系统产业在预测期内将是最大的。

预计自我血糖监测系统领域将在预测期内主导市场。这些系统应用广泛、易于使用且价格实惠，因而占据了巨大的市场占有率。这些设备使患者可以在家中或旅途中方便地检查自己的血糖值，使他们能够及时做出有关糖尿病管理的决定。许多国家已经制定了自我血糖监测系统的报销政策，患者和医疗保健提供者对这些设备的熟悉程度进一步支持了它们的市场优势。

妊娠糖尿病细分市场预计在预测期内复合年增长率最高

妊娠期间发生的妊娠糖尿病预计将成为血糖监测系统市场成长最快的部分。由于母亲年龄增加、肥胖和久坐的生活方式等因素，全球妊娠糖尿病的盛行率不断上升，推动了我这个患者群体对有效血糖监测解决方案的需求。此外，人们对妊娠糖尿病早期诊断和早期管理重要性的认识不断提高，预计将推动这一领域的快速成长。

比最大的地区

预计北美将占据血糖监测系统市场的最大份额。高糖尿病盛行率、完善的医疗基础设施以及有利的血糖监测设备报销政策奠定了该地区的主导地位。主要市场参与者的存在、先进的技术力以及对糖尿病管理的关注进一步推动了北美市场的成长。

复合年增长率最高的地区：

预计在预测期内，亚太地区的血糖监测系统市场成长率最高。由于快速都市化、生活方式改变和肥胖率上升等因素，该地区糖尿病人口正在显着增长，这带来了巨大的市场机会。由于中国和印度等国家庞大的患者群体和改善的医疗基础设施，预计将为市场成长做出重大贡献。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 技术分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球血糖监测系统市场：依产品类型

  • 自我血糖测量系统
    • 血糖值仪
    • 血糖值试纸
    • 采血针和采血装置
  • 连续血糖监测系统
    • 感应器
    • 发送器
    • 接收器

第六章全球血糖监测系统市场：依技术分类

  • 有创血糖监测
  • 非侵入性血糖监测

第七章全球血糖监测系统市场：按应用

  • 1型糖尿病
  • 2型糖尿病
  • 妊娠糖尿病

第八章全球血糖监测系统市场：按分销管道

  • 零售药房
  • 医院药房
  • 网路药房

第九章全球血糖监测系统市场：依最终用户分类

  • 医院和诊所
  • 居家照护环境
  • 诊断中心
  • 其他最终用户

第十章全球血糖监测系统市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第十一章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司概况

  • Roche Diagnostics
  • Abbott Laboratories
  • Medtronic plc
  • Dexcom, Inc.
  • Ascensia Diabetes Care
  • Johnson & Johnson
  • B. Braun Melsungen AG
  • ARKRAY, Inc.
  • Terumo Corporation
  • Ypsomed Holding AG
  • Nipro Corporation
  • Sanofi
  • Nova Biomedical
  • Trividia Health, Inc.
  • AgaMatrix, Inc.
  • Echo Therapeutics, Inc.
  • GlySens Incorporated
  • i-SENS, Inc.
  • Bionime Corporation
  • DarioHealth Corp.
Product Code: SMRC26429

According to Stratistics MRC, the Global Blood Glucose Monitoring Systems Market is accounted for $18.02 billion in 2024 and is expected to reach $26.74 billion by 2030 growing at a CAGR of 6.8% during the forecast period. Blood glucose monitoring systems are medical devices designed to measure and monitor the blood glucose levels of individuals with diabetes. These systems typically include glucose meters, testing strips, and lancets for self-testing, as well as continuous glucose monitoring systems that provide real-time glucose readings. Accurate monitoring helps diabetic patients manage their condition by facilitating timely adjustments to medication, diet, and lifestyle.

According to the estimations of the International Diabetes Federation (IDF), in 2021, around 537 million adults had diabetes and it is projected to reach around 783 million by 2045.

Market Dynamics:

Driver:

Rising prevalence of diabetes

The increasing global prevalence of diabetes is a major driver for the blood glucose monitoring systems market. As the number of people diagnosed with diabetes continues to rise, the demand for effective glucose monitoring solutions grows. Regular blood glucose monitoring is crucial for diabetes management, enabling patients to track their glucose levels, make informed decisions about their diet, exercise, and medication, and prevent complications. The rising diabetes burden, coupled with growing awareness about the importance of glucose control, is fueling the adoption of advanced blood glucose monitoring systems.

Restraint:

High cost of devices

These sophisticated devices often come with a premium price tag, which may limit their accessibility and adoption, especially in price-sensitive markets and among patients with limited financial resources. The ongoing expenses related to consumables, such as test strips and sensors, further add to the cost burden. The high upfront costs and recurring expenses may deter some patients and healthcare providers from embracing advanced glucose monitoring technologies, thus hindering market expansion.

Opportunity:

Expansion of home healthcare

With the increasing preference for remote monitoring and self-management of chronic conditions like diabetes, there is a rising demand for user-friendly and connected glucose monitoring devices that can be easily used at home. The integration of blood glucose monitoring systems with telemedicine platforms and mobile health applications enables patients to share their glucose data with healthcare providers in real-time, facilitating remote consultations and personalized treatment adjustments. The expansion of home healthcare services and the adoption of digital health technologies are expected to drive the uptake of advanced blood glucose monitoring systems.

Threat:

Product counterfeiting

Counterfeit devices, test strips, and sensors can compromise patient safety and lead to inaccurate glucose readings, potentially resulting in improper treatment decisions and adverse health outcomes. Counterfeit products may lack the necessary quality control and regulatory approvals, and their use can erode patient trust in legitimate blood glucose monitoring systems. Manufacturers face the challenge of protecting their intellectual property and ensuring the authenticity of their products in the face of counterfeit threats.

Covid-19 Impact:

The Covid-19 pandemic has highlighted the importance of remote monitoring and self-management of diabetes. With lockdowns and reduced access to healthcare facilities, many patients have relied on home-based glucose monitoring to manage their condition. The pandemic has accelerated the adoption of telemedicine and remote monitoring solutions, including connected blood glucose monitoring systems. However, the pandemic has also disrupted supply chains and led to delays in product launches and regulatory approvals, temporarily affecting market growth.

The self-monitoring blood glucose systems segment is expected to be the largest during the forecast period

The self-monitoring blood glucose systems segment is expected to dominate the market during the forecast period. The widespread availability, ease of use, and affordability of these systems contribute to their large market share. These devices enable patients to conveniently check their blood glucose levels at home or on the go, empowering them to make timely decisions about their diabetes management. The established reimbursement policies for self-monitoring blood glucose systems in many countries and the familiarity of patients and healthcare providers with these devices further support their dominant position in the market.

The gestational diabetes segment is expected to have the highest CAGR during the forecast period

The Gestational diabetes, which occurs during pregnancy, is expected to be the fastest-growing segment in the blood glucose monitoring systems market. The increasing prevalence of gestational diabetes worldwide, driven by factors such as rising maternal age, obesity, and sedentary lifestyles, is fueling the demand for effective glucose monitoring solutions in this patient population. Additionally, growing awareness about the importance of early diagnosis and management of gestational diabetes is expected to drive the rapid growth of this segment.

Region with largest share:

North America is expected to hold the largest share of the blood glucose monitoring systems market. The high prevalence of diabetes, well-established healthcare infrastructure, and favorable reimbursement policies for glucose monitoring devices contribute to the region's dominant position. The presence of key market players, advanced technological capabilities, and a strong emphasis on diabetes management further support market growth in North America.

Region with highest CAGR:

The Asia Pacific region is projected to experience the highest growth rate in the blood glucose monitoring systems market during the forecast period. The region's large and growing diabetes population, driven by factors such as rapid urbanization, changing lifestyles, and increasing obesity rates, presents a significant market opportunity. Countries like China and India, with their vast patient pools and improving healthcare infrastructure, are expected to be major contributors to market growth.

Key players in the market

Some of the key players in Blood Glucose Monitoring Systems Market include Roche Diagnostics, Abbott Laboratories, Medtronic plc, Dexcom, Inc., Ascensia Diabetes Care, Johnson & Johnson, B. Braun Melsungen AG, ARKRAY, Inc., Terumo Corporation, Ypsomed Holding AG, Nipro Corporation, Sanofi, Nova Biomedical, Trividia Health, Inc., AgaMatrix, Inc., Echo Therapeutics, Inc., GlySens Incorporated, i-SENS, Inc., Bionime Corporation and DarioHealth Corp.

Key Developments:

In October 2023, Terumo Corporation announced that it has agreed with U.S.-based Dexcom, Inc (Dexcom) to cease the distribution agreement for Dexcom's Continuous Glucose Monitoring Systems (CGM) in Japan. This decision was made in accordance with Dexcom's change in marketing strategy to shift from indirect distribution to direct sales in certain key markets, excluding the U.S.

In April 2023, Dexcom announced that the FDA cleared Stelo by Dexcom, the first glucose biosensor that doesn't require a prescription, making it easier for people with Type 2 diabetes not using insulin to access leading CGM technology.

In May 2022, Abbott announced the U.S. Food and Drug Administration (FDA) cleared its next-generation FreeStyle Libre 3 system for use by people four years and older6 living with diabetes. "The FreeStyle Libre 3 system is a direct result of listening to our customers - and giving them the innovation and sensing technology they've been looking for," said Jared Watkin, senior vice president of Abbott's diabetes care business.

Product Types Covered:

  • Self-Monitoring Blood Glucose Systems
  • Continuous Glucose Monitoring Systems

Technologies Covered:

  • Invasive Blood Glucose Monitoring
  • Non-Invasive Blood Glucose Monitoring

Applications Covered:

  • Type 1 Diabetes
  • Type 2 Diabetes
  • Gestational Diabetes

Distribution Channels Covered:

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

End Users Covered:

  • Hospitals and Clinics
  • Home Care Settings
  • Diagnostic Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats

3.6 Product Analysis

  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Blood Glucose Monitoring Systems Market, By Product Type

  • 5.1 Introduction
  • 5.2 Self-Monitoring Blood Glucose Systems
    • 5.2.1 Blood Glucose Meters
    • 5.2.2 Blood Glucose Test Strips
    • 5.2.3 Lancets and Lancing Devices
  • 5.3 Continuous Glucose Monitoring Systems
    • 5.3.1 Sensors
    • 5.3.2 Transmitters
    • 5.3.3 Receivers

6 Global Blood Glucose Monitoring Systems Market, By Technology

  • 6.1 Introduction
  • 6.2 Invasive Blood Glucose Monitoring
  • 6.3 Non-Invasive Blood Glucose Monitoring

7 Global Blood Glucose Monitoring Systems Market, By Application

  • 7.1 Introduction
  • 7.2 Type 1 Diabetes
  • 7.3 Type 2 Diabetes
  • 7.4 Gestational Diabetes

8 Global Blood Glucose Monitoring Systems Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Retail Pharmacies
  • 8.3 Hospital Pharmacies
  • 8.4 Online Pharmacies

9 Global Blood Glucose Monitoring Systems Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals and Clinics
  • 9.3 Home Care Settings
  • 9.4 Diagnostic Centers
  • 9.5 Other End Users

10 Global Blood Glucose Monitoring Systems Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Roche Diagnostics
  • 12.2 Abbott Laboratories
  • 12.3 Medtronic plc
  • 12.4 Dexcom, Inc.
  • 12.5 Ascensia Diabetes Care
  • 12.6 Johnson & Johnson
  • 12.7 B. Braun Melsungen AG
  • 12.8 ARKRAY, Inc.
  • 12.9 Terumo Corporation
  • 12.10 Ypsomed Holding AG
  • 12.11 Nipro Corporation
  • 12.12 Sanofi
  • 12.13 Nova Biomedical
  • 12.14 Trividia Health, Inc.
  • 12.15 AgaMatrix, Inc.
  • 12.16 Echo Therapeutics, Inc.
  • 12.17 GlySens Incorporated
  • 12.18 i-SENS, Inc.
  • 12.19 Bionime Corporation
  • 12.20 DarioHealth Corp.

List of Tables

  • Table 1 Global Blood Glucose Monitoring Systems Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Blood Glucose Monitoring Systems Market Outlook, By Product Type (2022-2030) ($MN)
  • Table 3 Global Blood Glucose Monitoring Systems Market Outlook, By Self-Monitoring Blood Glucose Systems (2022-2030) ($MN)
  • Table 4 Global Blood Glucose Monitoring Systems Market Outlook, By Blood Glucose Meters (2022-2030) ($MN)
  • Table 5 Global Blood Glucose Monitoring Systems Market Outlook, By Blood Glucose Test Strips (2022-2030) ($MN)
  • Table 6 Global Blood Glucose Monitoring Systems Market Outlook, By Lancets and Lancing Devices (2022-2030) ($MN)
  • Table 7 Global Blood Glucose Monitoring Systems Market Outlook, By Continuous Glucose Monitoring Systems (2022-2030) ($MN)
  • Table 8 Global Blood Glucose Monitoring Systems Market Outlook, By Sensors (2022-2030) ($MN)
  • Table 9 Global Blood Glucose Monitoring Systems Market Outlook, By Transmitters (2022-2030) ($MN)
  • Table 10 Global Blood Glucose Monitoring Systems Market Outlook, By Receivers (2022-2030) ($MN)
  • Table 11 Global Blood Glucose Monitoring Systems Market Outlook, By Technology (2022-2030) ($MN)
  • Table 12 Global Blood Glucose Monitoring Systems Market Outlook, By Invasive Blood Glucose Monitoring
  • Table 13 Global Blood Glucose Monitoring Systems Market Outlook, By Non-Invasive Blood Glucose Monitoring (2022-2030) ($MN)
  • Table 14 Global Blood Glucose Monitoring Systems Market Outlook, By Application (2022-2030) ($MN)
  • Table 15 Global Blood Glucose Monitoring Systems Market Outlook, By Type 1 Diabetes (2022-2030) ($MN)
  • Table 16 Global Blood Glucose Monitoring Systems Market Outlook, By Type 2 Diabetes (2022-2030) ($MN)
  • Table 17 Global Blood Glucose Monitoring Systems Market Outlook, By Gestational Diabetes (2022-2030) ($MN)
  • Table 18 Global Blood Glucose Monitoring Systems Market Outlook, By Distribution Channel (2022-2030) ($MN)
  • Table 19 Global Blood Glucose Monitoring Systems Market Outlook, By Retail Pharmacies (2022-2030) ($MN)
  • Table 20 Global Blood Glucose Monitoring Systems Market Outlook, By Hospital Pharmacies (2022-2030) ($MN)
  • Table 21 Global Blood Glucose Monitoring Systems Market Outlook, By Online Pharmacies (2022-2030) ($MN)
  • Table 22 Global Blood Glucose Monitoring Systems Market Outlook, By End User (2022-2030) ($MN)
  • Table 23 Global Blood Glucose Monitoring Systems Market Outlook, By Hospitals and Clinics (2022-2030) ($MN)
  • Table 24 Global Blood Glucose Monitoring Systems Market Outlook, By Home Care Settings (2022-2030) ($MN)
  • Table 25 Global Blood Glucose Monitoring Systems Market Outlook, By Diagnostic Centers (2022-2030) ($MN)
  • Table 26 Global Blood Glucose Monitoring Systems Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.